Home/ Stocks/ IRON

Disc Medicine, Inc. Common Stock

IRON XNAS

$68.26 +0.73 (+1.08%) ▲ 15-min delayed

Open

$67.65

High

$70.30

Low

$67.37

Volume

656.3K

Market Cap

$2.61B

About Disc Medicine, Inc. Common Stock

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 155 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-63,504,000	$-1.65
FY 2025	$0	$-212,184,000	$-6.01
Q3 2025	$0	$-62,321,000	$-1.77
Q2 2025	$0	$-55,247,000	$-1.58

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for IRON yet. Check out our latest market news or earnings calendar.

Get IRON Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Disc Medicine, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.